Home＞ACADEMIA
DPP-4 Inhibitor Prevents Deterioration in Cardiac Diastolic Function in Diabetes Patients: Research Sub-Analysis(May.26.2017)
The dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin significantly inhibited deterioration in cardiac diastolic function in diabetes patients, according to results of a clinical research sub-analysis announced by Saga University on May 24 ...
(LOG IN FOR FULL STORY)
-
- Opdivo-Induced Myasthenia Gravis Tends to Become Severe: Keio Researchers Aug.21
- Japan Gastric Cancer Association to Wait for Opdivo Nod before Guidelines Update, Keytruda Won’t Make It This Time Aug.16
- NCCHD to Launch Panel to Study Real-World Drug Use in Children, Findings Might Be Used for Label Revisions Aug.08
- Kyoto Univ. to Commence Trial of Drug Candidate Discovered in iPS Cells Research for Rare Bone Disease Aug.03
- Drug Vial Optimization Reduces Drug Expenditure, with Biggest Savings for Opdivo: Study Aug.02
- Leftover Spinraza in 9-Million-Yen Vial Must Be Discarded, Can’t Be Saved for Next Time: MHLW Official(Aug.23)
- 1st Patient Dosed in PIII for Gilteritinib as Post-HCT AML Maintenance Therapy: Astellas(Aug.23)
- Spinraza’s 9.32 Million Yen Price Tag OK’ed for Listing on Aug. 30(Aug.23)
- Takeda Files Japan NDA for Entyvio(Aug.23)
- External Activities of Takeda Unit Axcelead to Go Full Throttle This Autumn: President(Aug.23)
- The next ebook update will be provided on August 28.
